Genscript Biotech Corporation

Good day and thank you for standing by. Welcome to GenScript 2025 Annual Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Mr. Phil Zhou, CFO. Please go ahead.

Hello, everyone. This is Phil Zhou, CFO at Chainscript. Welcome to 2025 Annual Results Conference Call. Joining me on the call today are Mr. Robin Meng, Chairman of the Board, Ms. Sherry Zhao, Rotating CEO of Chainscript, Dr. Ray Chen, President of Junescript Life Science Group. Dr. Icy Bai, General Manager of BestSign. Mr. Alan Guo, CEO of Propel. During today's call, we will be making statements about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, which may constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements because of various important risk factors and the changing market conditions. We do not undertake any obligation to publicly update any forward-looking statements. Today, Sherry will start with a company highlight and our business heads will present highlights for each segment. I will then guide you through 1025 financial performance, Or in last, Sherry will update our business focus and the 2026 four-year guidance. We also have a Q&A session at the end of the call. As a reminder, today's presentation materials can be accessed in the investor relations section of the company's website. Now, I will hand it over to Sherry.

Thank you, Phil. In 2025, Genscript Group delivered accelerated growth despite navigating a complex geopolitical and microeconomic. Our success was powered by leveraging our global operations, robust management frameworks, and technological expertise, allowing us to transform challenges into opportunities. The biotech sector delivered three key headlights in 2025, renewed funding flows AI-driven innovation, and record-breaking Chinese auto licensing, all of which directly enhanced our growth trajectory. In terms of our financial performance, we achieved outstanding results. Group revenue surged by 61.4% year-over-year. Adjusted net profit reached nearly $230 million. Our growth stems from our four strategic drivers. First, our gene-to-protein synergy strategy successfully integrated the capabilities across the life sciences value chain, creating powerful cross-business momentum. Second, our global expansion accelerated performance across all three business segments through targeted market investment. Third, our productization strategy draws tangible results. Both the life science group products and industrial enzyme business delivered solid revenue contributions. Fourth, operational excellence through automated manufacturing and AI-powered R&D shortened development cycles and boosted manufacturing efficiency significantly. Regarding our associate company, Legend Biotech, we are proud to share two milestones. Legend Biotech's cavity therapy achieved four-year profitability in 2025. The adjusted net profit turned positive in Q4 2025, and the 2025 four-year adjusted net loss significantly narrowed to $33.1 million. we are confident that agents strengthening financial position will create long-term positive impact for our group. In 2025, we made significant progress in sustainability. In recent years, ESG has become a critical competitive differentiator for global companies. An increasing number of our customers worldwide now regard ESG ratings as a good standard when selecting partners. Through years of strategic investment and continuous management optimization, Genscript has achieved industry-leading ESG performance. In 2025, MSCI upgraded our ESG rating to AA. we were also selected for inclusion in the FTSE for Good Index series. Additionally, we received a silver medal in the Ecovades Global Supply Chain Sustainability Assessment. Just last month, Janscript was further honored by being named to the 2026 S&P Global Sustainability Yearbook. These ESG achievements reflect our ongoing efforts across environmental stewardship, labor practices, corporate governance, and beyond, all driving continuous improvement in our management systems. Now, I will hand over to Dr. Rui Chen, president of GenScript Life Science Group, to share Life Science Group's business highlights.